ClinicalTrials.gg
Not yet recruitingNCT07159659Updated Oct 21, 2026

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

An interventional study of MCT Diet in Thoracic Neoplasms, sponsored by Chinese University of Hong Kong. Not yet recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 21, 2026Now Not yet recruitingStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Lung resection, a critical treatment for various thoracic diseases, including lung cancer, often necessitates prolonged hospitalization due to rare but severe postoperative complications such as chyle leaks, with an occurrence of 0.25%-3%, prolonging chest drainage, and delaying recovery. Therefore, effective postoperative care is essential for optimizing outcomes, reducing complications, and expediting recovery.

Recent studies have highlighted the significant potential of medium-chain triglyceride (MCT) diets, owing to their unique absorption pathway and metabolic properties. MCT contains mainly medium-chain fatty acids (MCFA), which is absorbed in the intestine and transported to the liver via the portal system instead of the lymphatic system. This helps to bypass the lymphatic system, thereby reducing the volume of lymph. MCFAs also provide better energy utilization in stressed condition since it does not require carnitine shuttle upon metabolism, which is beneficial to post-operation recovery.

Several studies have demonstrated the benefits of MCT diets in managing chyle leaks and supporting gastrointestinal recovery, particularly in conditions that strain the lymphatic system. For instance, short-term MCT-enriched diets have been associated with improved post-operation recovery of gastrointestinal, hepatic and renal functions, reduced total chest drainage volumes, and shorter hospital stay when compared to regular diet groups.

Patients with post-operative chyle leak following thoracic surgery are often given an MCT diet to reduce chest drain volume and hence shorten hospital stay. Based on the successful use of MCT diet on patients with chyle leak after lobectomy, it is hypothesized that patients with chylothorax provided with post-operative MCT diet can also shorten hospital stay by decreasing chest drainage. Therefore, a prospective and randomized trial is designed to investigate how post-operative MCT diet in lung resection patients without chylothorax may affect hospital stay and post-operative recovery.

Read the detailed description

This study is a single-center, prospective, randomized trial designed to investigate how a post-operative diet enriched with MCT affects recovery in patients undergoing video-assisted thoracic surgery (VATS). Medical students from the Chinese University of Hong Kong, under the supervision of the principal investigator, will conduct the study, including obtaining consent and collecting data. Experienced surgeons at the Prince of Wales Hospital will perform the VATS procedures.

2.2 Hypotheses

  1. MCT diet can speed up post-operative recovery and shorten hospital length of stay.
  2. MCT diet poses no adverse effects in post-operative recovery for patients without chyle leak following lung surgery.
  3. The use of MCT diet after discharge for 2 weeks can enhance patient recovery and possibly reduce readmissions or complications.
02

Conditions studied

  • Thoracic Neoplasms

Browse trials for

Keywords

  • Medium Chain Triglyceride Diet
  • Lung Resection
  • Video-assisted thoracoscopic surgery
03

In context

Thoracic Neoplasms

115 studies on the registry are indexed under Thoracic Neoplasms; 30 are open to participants now.

This study's planned enrollment of 210 is above the median of 61 across 86 interventional studies indexed under Thoracic Neoplasms.

Browse Thoracic Neoplasms studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General Inclusion Criteria for All procedures:

  1. Age between 18 - 80 years
  2. \<35 kg/m2
  3. Suitable for minimally invasive surgery
  4. Willingness to participate as demonstrated by giving

Project-specific Criteria:

1. Patients performed lobectomy with lymph node dissection

Exclusion criteria

Exclusion Criteria:

Patient general exclusion criteria:

  1. to general anesthesia
  2. Severe concomitant illness that drastically shortens or increases the risk of therapeutic intervention
  3. Untreated active infection
  4. Non-correctable coagulopathy
  5. Emergency surgery
  6. Vulnerable population (e.g. mentally disabled, pregnancy)

Project-specific Criteria

  1. Segmentectomy
  2. Pleurodesis
  3. Esophageal procedures
  4. Redo/readmitted patients for lung resection
  5. Chylothorax (Triglyceride > 110 mL, excluded at day 1 routine lab check)
  6. Air leak (> 30 mL/min when back to ward)
  7. Heart Failure
  8. Renal failure (estimated \< 30; CKD grading stage 4-5)
  9. Moderate to severe adhesion (defined at randomization by surgeon; criteria include estimated surface area of adhesion and staging)
  10. History of tuberculosis or empyema
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • No intervention
    Control Group

    Patients in the control group will receive a standard hospital diet consistent with routine postoperative nutritional care after lobectomy with lymph node dissection. This diet does not include medium-chain triglyceride (MCT) supplementation and serves as a comparator to evaluate the effects of the MCT diet on postoperative recovery

  • Experimental
    MCT diet during hospital stay

    Patients will receive a medium-chain triglyceride (MCT)-enriched diet during their hospital stay following lobectomy with lymph node dissection. The MCT diet is administered as part of the postoperative nutritional regimen to evaluate its impact on recovery outcomes

    Dietary Supplement: MCT Diet

  • Experimental
    MCT diet during hospital stay and 2 weeks after discharge

    Participants will receive a medium-chain triglyceride (MCT) diet during their hospital stay and for two weeks following discharge. This aims to evaluate the effects of continued MCT dietary supplementation on postoperative recovery outcomes after lobectomy with lymph node dissection

    Dietary Supplement: MCT Diet

Interventions

  • Dietary supplementMCT Diet

    MCT diet for patients following lung resection

06

What researchers measure

Primary outcomes

  1. hospital length of stay (LOS)

    hospital length of stay (LOS), which is hypothesized to be reduced following the administration of an MCT diet. Currently, patients undergoing lobectomy using VATS have a median LOS of approximately 3-4 days. The study aims to investigate whether MCT diet interventions can reduce this to 2 days, representing a 30% reduction in hospital stay.

    Time frame: From the end of the lung resection procedure until the time of patient discharge, assessed up to 7 days post-surgery

Secondary outcomes

  1. Total Chest Drain Output (mL)

    Chest drain output indirectly reflects recovery status. The total chest drain output will be measured using the Medela digital chest drainage system, which is routinely used for patients undergoing lobectomy. Compared to manual drainage system, this system allows more precise monitoring of fluid output. This information will help evaluate the overall impact of the MCT diet on postoperative recovery, particularly in reducing fluid drainage.

    Time frame: From the end of the lung resection procedure until the time of chest drain removal assessed up to 7 days post-surgery

  2. Patient Satisfaction and Tolerability

    Patient-reported outcomes will be assessed using a quality of life (QoL) questionnaire, which is an established tool for evaluating recovery after surgery. The questionnaire will include: * Patient satisfaction with their recovery process * Tolerability of the MCT diet * Any challenges experienced during the diet, including adherence and acceptability

    Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge

  3. Number of Participants with Symptoms Associated with MCT Diet

    Patients will be monitored for any gastrointestinal discomfort associated with the MCT diet, including: * Diarrhea * Constipation * Bloating * Increased flatus Reports of these symptoms will be collected during the hospital stay and follow-up visits to assess the safety and tolerability of the MCT diet.

    Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge

  4. Number of patients with Infection symptoms

    · Observing for symptoms such as fever or shortness of breath (SOB), which will be incorporated into the QoL questionnaire

    Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge

  5. Number of patients with infection risk

    Regular checks for pleural-based complications, such as effusion, through chest X-rays (performed before discharge and during follow-ups)

    Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 22 interventional studies with no phase under Thoracic Neoplasms, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 3 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Nov 2026, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Sep 8, 2025
StartEst.
Nov 1, 2026was Mar 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Aug 30, 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Not yet recruiting
changed Oct 21, 2026
Start date
Mar 19, 2026→Nov 1, 2026
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Not yet recruiting
    Start date Mar 19, 2026→Nov 1, 2026
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07159659
Responsible party
Calvin Sze Hang Ng (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Sep 8, 2025
Start date
Nov 1, 2026 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Calvin Sze Hang Ng
Contact
calvinng@surgery.cuhk.edu.hk
+852 3505 2618

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion